Biosplice Therapeutics Inc. has prepared and tested 4-alkoxypyrrolo[2,1-F][1,2,4]triazines acting as dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors potentially useful for the treatment of Alzheimer’s disease.
Biosplice Therapeutics Inc. has discovered dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes and Alzheimer’s disease.
Biosplice Therapeutics Inc. has entered a collaboration with Novo Nordisk A/S to develop first-in-class drug candidates for the treatment of diabetes. Biosplice is developing highly selective and potent dual-specificity tyrosine-regulated kinase (DYRK) inhibitors to stimulate insulin-secreting β-cell proliferation for the treatment of diabetes.
Biosplice Therapeutics Inc. has disclosed dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes and Alzheimer’s disease.
The Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP) has awarded funding to Biosplice Therapeutics Inc.’s collaboration with The Roskamp Institute aimed at developing novel therapies for traumatic brain injury (TBI).
Biosplice Therapeutics Inc. has prepared and tested pyrrolo[2,1-F][1,2,4]triazines derivatives acting as dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and reported to be useful for the treatment of cancer, diabetes and neurological disorders.
Biosplice Therapeutics Inc. has described 1H-pyrrolo[2,3-b]pyridines acting as dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes and neurological disorders.
